Detection of Differentially Expressed microRNAs in Serum of Pancreatic Ductal Adenocarcinoma Patients: miR-196a Could Be a Potential Marker for Poor Prognosis
Detection of Differentially Expressed microRNAs in Serum of Pancreatic Ductal Adenocarcinoma Patients: miR-196a Could Be a Potential Marker for Poor Prognosis
复制标题
胰腺导管腺癌患者血清中差异表达的 microRNA 检测：miR-196a 可能是预后不良的潜在标志物
DOI：
10.1007/s10620-010-1285-3
复制
发表时间：
2011-02-01
影响因子：
3.1
通讯作者：
Li, Zhaoshen
中科院分区：
文献类型：
--
作者：
Kong, Xiangyu;Du, Yiqi;Li, Zhaoshen
背景技术MicroRNA（miRNAs）长期以来被认为在循环中保持稳定，目的探讨胰腺导管腺癌（PDAC）患者血清中miRNAs的表达水平及其异常表达情况，探讨血清miRNAs是否可作为胰腺导管腺癌诊断和预后的生物标志物。方法选取2007年8月至2009年1月期间确诊的35例PDAC患者。15例慢性胰腺炎（CP）患者和15例健康人血清作为对照。定量实时聚合酶链反应分析，具体成熟的miRNAs被用来量化这些PDAC相关的血清miRNAs的相对水平。ResultsOf七个检测到的miRNAs，三个被确定为差异表达的PDAC和对照组。miR-21能够区分PDAC患者与CP（p= 0.033）和健康受试者（p= 0.001），而miR-155和miR-196 a能够区分具有患病胰腺（PDAC/CP）的血清与正常胰腺（分别为p= 0.0002和0.010）。不可切除的PDAC（III期和IV期）患者的血清miR-196 a表达水平显著高于可切除的（I期和II期）患者（p= 0.001）。此外，血清miR-196 a表达水平被发现在预测PDAC患者的中位生存时间方面具有潜在价值（高水平miR-196 a，6.1个月，（95% CI，4.49-7.72）对比低水平miR-196 a，12.00个月，结论血清miR-196 a水平可作为PDAC预后判断及手术方式选择的无创性指标。
BackgroundMicroRNAs (miRNAs) have long been established to remain stable in circulation, and dysregulated miRNAs in serum of tumor patients could potentially serve as novel biomarkers.AimsTo determine whether certain serum miRNAs could represent potential diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma (PDAC).MethodsAbout 35 patients diagnosed with PDAC at different stages between August 2007 and January 2009 were enrolled in this study. Sera from 15 chronic pancreatitis (CP) patients and 15 healthy individuals were treated as controls. Quantitative real-time polymerase chain reaction assays specific to mature miRNAs were used to quantify the relative levels of those PDAC-associated serum miRNAs.ResultsOf the seven miRNAs detected, three were identified as differentially expressed in PDAC and control groups. miR-21 was able to distinguish PDAC patients from CP (p= 0.033) and healthy subjects (p= 0.001), whereas miR-155 and miR-196a were able to differentiate sera with sick pancreas (PDAC/CP) from normal pancreas (p= 0.0002 and 0.010, respectively). Serum miR-196a expression levels in unresectable PDAC (stages III and IV) patients were significantly higher than those in resectable (stages I and II) patients (p= 0.001). Furthermore, serum miR-196a expression level was found to have a potential value in predicting median survival time of PDAC patients (high-level miR-196a, 6.1 months, (95% CI, 4.49–7.72) versus low-level miR-196a, 12.00 months, (95% CI, 5.92–18.08),p= 0.007).ConclusionsSerum miR-196a could be a potential noninvasive marker for PDAC prognosis and selection of laparotomy.